Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy

Autor: Bodhraj Acharya, Kamal D. Moudgil, Shivaprasad H. Venkatesha, Rakeshchandra R. Meka
Rok vydání: 2019
Předmět:
Male
Drug
Cell Survival
Surface Properties
Drug Compounding
media_common.quotation_subject
Anti-Inflammatory Agents
Biomedical Engineering
Medicine (miscellaneous)
Arthritis
Bioengineering
02 engineering and technology
Development
Pharmacology
Dexamethasone
03 medical and health sciences
Human Umbilical Vein Endothelial Cells
medicine
Animals
Humans
Tissue Distribution
General Materials Science
Molecular Targeted Therapy
030304 developmental biology
media_common
0303 health sciences
Liposome
business.industry
Phosphatidylethanolamines
021001 nanoscience & nanotechnology
medicine.disease
Arthritis
Experimental
Rats
Targeted drug delivery
Arthritis therapy
Rats
Inbred Lew
Rheumatoid arthritis
Liposomes
Drug delivery
Phosphatidylcholines
Joints
Peptides
0210 nano-technology
business
Research Article
medicine.drug
Zdroj: Nanomedicine (Lond)
ISSN: 1748-6963
1743-5889
Popis: Aim: Rheumatoid arthritis is an autoimmune disease affecting the joints. Antiarthritic drugs are given systemically, thereby exposing various healthy organs to these drugs, resulting in adverse reactions. Accordingly, there is an urgent need for targeted drug delivery methods for inflamed joints. Materials & methods: We developed a liposomal drug delivery system using a novel peptide ligand (CKPFDRALC) named ART-2, which homes to the inflamed joints when injected intravenously to rats with adjuvant-induced arthritis. Results: The ART-2-coated liposomes encapsulating an antiarthritic drug, dexamethasone (DEX), were more effective in inhibiting arthritis progression than control-DEX liposomes or free DEX, despite a comparable safety profile. Conclusion: Peptide-targeted therapy has advantages over conventional drug delivery and can be adapted for rheumatoid arthritis therapy.
Databáze: OpenAIRE
Externí odkaz: